Bachem offers complimentary white papers on innovative products, services or processes in peptide NCEs and oligonucleotide NCEs research, as well as technical information on custom peptide synthesis.
A New Turn in Peptide Purification
Innovation is a central pillar of Bachem’s success. Our dedicated teams explore and develop new technologies to bring innovative solutions to our partner’s needs. Here, we will introduce a new innovation that represents a new turn in peptide purification.
Read the full white paper on a new turn in peptide purification.
Continuous Chromatography – Pushing the boundaries of peptide and oligonucleotide production
During the manufacturing of a peptide API, well-established purification is crucial for achieving high purity and yield, and at the same time is a major determinant for the cost efficiency and process productivity.
Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) has shown to achieve substantially higher capacity and yield than single-column batch processes. This innovative purification process leads to time savings, economic advantages and a lower environmental footprint.
Download White Paper
By completing this form, the requested document will be sent directly to your email.
Greener purification at large-scale
An oligonucleotide case study
Resembling a new era of innovative drug development, the interest of the biopharma industry in the oligonucleotide markets has grown significantly in the past five years.
In 2021, the US Food and Drug Administration (FDA) approved the first-in-class siRNA to lower cholesterol – a drug with a multi-ton potential to treat millions of patients per year. Moving forward, the demand for oligonucleotide batch size is likely to increase as well as the need for large-scale manufacturing capacity to support this growth.
Download Case study
By completing this form, the requested document will be sent directly to your email.
Reducing Solvent Consumption for Large-scale Peptide API Manufacturing
An peptide case study
Resembling a new era of innovative drug development, the interest of the biopharma industry in the peptide and oligonucleotide markets has risen significantly in the past five years. The advent of oral and inhaled peptide products has driven demand for these active pharmaceutical ingredients (APIs).
Between 2018 and 2020, the average peptide manufacturing batch size increased by 2.3 times in response to a wider variety of peptide drug modalities entering the market. Furthermore, with the launch of new glucagon-like peptide (GLP) analogs targeting metabolic diseases like diabetes and obesity, there is a growing need for large-scale manufacturing of these APIs to treat a large patient population.
Download Case study
By completing this form, the requested document will be sent directly to your email.
Microspheres and Nanoparticles for Peptide Delivery
Proteins and peptides fulfill an irreplaceable role as medicines due to their high affinity, specificity, low toxicity, and ability to alter protein-protein interactions. They are widely recognized as therapeutic agents in the treatment of a variety of conditions, including diabetes, osteoporosis, nonHodgkin’s lymphoma, and leukemia. Clinical development is on-going as the pharmaceutical industry works to harness the potential of peptides for many other conditions. While incredible progress has been made in designing peptide- and protein-based drugs for multiple therapeutic uses, challenges remain. This white paper explores challenges of peptide- and protein-based new chemical entities [NCEs]including potential chemical and physical instabilities, enzymatic degradation, and their rapid elimination from circulation.
Read the full white paper on microspheres nanoparticle.
